DiaMedica Inc. Amends the Expiry Date of Warrants

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN
THE UNITED STATES


Further to its previously announced application to the TSX Venture Exchange,
DiaMedica Inc. (TSX VENTURE:DMA) has received approval from the TSX Venture
Exchange to amend 1,055,600 warrants (the "Warrants") of DiaMedica by extending
the expiry date from May 8, 2014 to February 8, 2015. An amended and restated
warrant indenture governing the Warrants has been filed concurrently herewith on
SEDAR at www.sedar.com. 


About DiaMedica

DiaMedica Inc. is a publicly traded (TSX VENTURE:DMA) clinical stage
biopharmaceutical company focused on the discovery and development of novel
therapies to treat diabetes and the complications associated with diabetes.
DiaMedica's lead clinical stage compound, DM199, is a recombinant human protein
known as rhKLK1 that represents a novel approach to treating diabetes and
associated complications. DiaMedica is also developing a monoclonal antibody,
DM204 for the treatment of Type 2 diabetes, which is in preclinical development.


DiaMedica is listed on the TSX Venture Exchange in Canada under the trading
symbol 'DMA'.


Neither the TSX Venture Exchange nor its Regulation Services Provider (as that
term is defined in the policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of the contents of this News
Release.


FOR FURTHER INFORMATION PLEASE CONTACT: 
DiaMedica Inc.
Rick Pauls
President & CEO
763-710-4455
[e-mail]